SRx Health CEO granted warrants, preferred and stock
SRx Health Solutions, Inc. Chief Executive Officer Kent Douglas Cunningham reported multiple equity awards that increase his ownership exposure, with no sales disclosed.
Rhea-AI Filing Summary
SRx Health Solutions, Inc. Chief Executive Officer Kent Douglas Cunningham reported multiple equity awards that increase his ownership exposure, with no sales disclosed. On March 16, 2026, he received 247,522 Series B Warrants with an exercise price of $0.3182 per share, exercisable into the same number of common shares and expiring on March 16, 2029. On the same date he was also granted 63 shares of Series B Preferred Stock at $800 per share. Earlier awards include common stock grants of 231,193 shares on August 25, 2025 and 200,000 shares on December 3, 2025, both recorded as grants/awards rather than open-market purchases. One 44,464-share common stock position is held indirectly through Halo Spin-Out SPV Inc. The filing also reports a prior grant of 8,000 stock options with a $5.00 exercise price and 8,000 underlying common shares, along with several smaller common stock awards, all categorized as compensation-related acquisitions.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 910,645 shares
Grant/Award
9 txns
Insider
Cunningham Kent Douglas
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Series B Warrants | 247,522 | $0.3182 | $79K |
| Grant/Award | Series B Preferred Stock | 63 | $800.00 | $50K |
| Grant/Award | Common Stock | 200,000 | $0.39 | $78K |
| Grant/Award | Common Stock | 44,464 | $0.33 | $15K |
| Grant/Award | Common Stock | 231,193 | $0.404 | $93K |
| Grant/Award | Common Stock | 84,906 | $1.59 | $135K |
| Grant/Award | Common Stock | 71,770 | $2.09 | $150K |
| Grant/Award | Stock Options - Right to Buy | 8,000 | $5.00 | $40K |
| Grant/Award | Common Stock | 22,727 | $4.17 | $95K |
Holdings After Transaction:
Stock Options - Right to Buy — 8,000 contracts (Direct);
Series B Warrants — 247,522 contracts (Direct);
Common Stock — 655,060 shares (Direct);
Common Stock — 455,060 shares (Indirect, Indirectly owned through ownership in Halo Spin-Out SPV Inc.);
Series B Preferred Stock — 63 shares (Direct)
Key Figures
Series B Warrants granted: 247,522 warrants at $0.3182
Series B Preferred Stock granted: 63 shares at $800
Common stock award: 231,193 shares at $0.4040
+5 more
8 metrics
Series B Warrants granted
247,522 warrants at $0.3182
Grant on March 16, 2026; exercisable into 247,522 common shares
Series B Preferred Stock granted
63 shares at $800
Preferred stock grant on March 16, 2026
Common stock award
231,193 shares at $0.4040
Grant on August 25, 2025; compensation-related acquisition
Common stock award
200,000 shares at $0.3900
Grant on December 3, 2025; total direct common shares then 655,060
Indirect common shares
44,464 shares at $0.3300
Held indirectly via Halo Spin-Out SPV Inc. from September 26, 2025 grant
Stock options granted
8,000 options at $5.00
Grant on June 26, 2024; underlying 8,000 common shares; expire June 26, 2034
Common stock grant
84,906 shares at $1.59
Grant on April 25, 2025; total direct common shares then 179,403
Initial reported common stock grant
22,727 shares at $4.17
Grant on June 26, 2024; first common stock award in this series
Key Terms
Series B Warrants, Series B Preferred Stock, Stock Options - Right to Buy, grant/award acquisition, +1 more
5 terms
Series B Warrants financial
"security_title: "Series B Warrants" with 247,522 underlying common shares"
Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.
Series B Preferred Stock financial
"security_title: "Series B Preferred Stock" with 63.0000 shares at $800.0000"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Stock Options - Right to Buy financial
"security_title: "Stock Options - Right to Buy" for 8,000.0000 shares at $5.0000"
grant/award acquisition financial
"transaction_action: "grant/award acquisition" for all A-coded transactions"
indirectly owned financial
"nature_of_ownership: "Indirectly owned through ownership in Halo Spin-Out SPV Inc.""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did SRXH CEO Kent Douglas Cunningham report?
Kent Douglas Cunningham reported several equity awards, all classified as acquisitions, not open-market trades. These include grants of Series B Warrants, Series B Preferred Stock, common stock, and stock options, reflecting compensation-related increases in his exposure to SRx Health Solutions, Inc. shares over multiple dates.
How many Series B Warrants were granted to the SRXH CEO and at what price?
Cunningham received 247,522 Series B Warrants on March 16, 2026, each with an exercise price of $0.3182. These warrants are exercisable into 247,522 shares of common stock and expire on March 16, 2029, giving him additional leveraged exposure to future common share value.
What preferred stock awards did SRXH grant to its CEO in this filing?
On March 16, 2026, Cunningham was granted 63 shares of Series B Preferred Stock at $800 per share. This award is categorized as a grant or award acquisition, indicating it was part of compensation rather than an open-market purchase, and adds a preferred equity layer to his holdings.
Did the SRXH Form 4 show any insider sales by the CEO?
The Form 4 shows no sales; all reported transactions are coded as acquisitions (A) and described as grants or awards. These include common stock, preferred stock, warrants, and options, indicating compensation-related awards rather than disposals of existing holdings in SRx Health Solutions, Inc.
Does the SRXH CEO hold any common stock indirectly?
Yes. The filing shows an award of 44,464 common shares on September 26, 2025 held indirectly through Halo Spin-Out SPV Inc. The nature of ownership is described as indirectly owned through that entity, distinguishing it from Cunningham’s directly held SRx Health Solutions, Inc. shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
